F P Barry

Summary

Affiliation: Osiris Therapeutics
Country: USA

Publications

  1. ncbi Mesenchymal stem cells: clinical applications and biological characterization
    Frank P Barry
    Osiris Therapeutics Inc, 2001 Aliceanna Street, Baltimore, MD 21231, USA
    Int J Biochem Cell Biol 36:568-84. 2004
  2. ncbi Mesenchymal stem cell therapy in joint disease
    Frank P Barry
    Osiris Therapeutics Inc, 2001 Aliceanns Street, Baltimore, MD 21231, USA
    Novartis Found Symp 249:86-96; discussion 96-102, 170-4, 239-41. 2003
  3. ncbi Biology and clinical applications of mesenchymal stem cells
    Frank P Barry
    Osiris Therapeutics Inc, 2001 Aliceanna St, Baltimore, MD 21231, USA
    Birth Defects Res C Embryo Today 69:250-6. 2003
  4. ncbi The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105)
    F P Barry
    Osiris Therapeutics Inc, 2001 Aliceanna Street, Baltimore, Maryland, 21231, USA
    Biochem Biophys Res Commun 265:134-9. 1999
  5. ncbi Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components
    F Barry
    Osiris Therapeutics, Inc, 2001 Aliceanna Street, Baltimore, Maryland 21231, USA
    Exp Cell Res 268:189-200. 2001
  6. ncbi The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells
    F Barry
    Osiris Therapeutics, Inc, Baltimore, Maryland 21231, USA
    Biochem Biophys Res Commun 289:519-24. 2001
  7. ncbi Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow
    A M Mackay
    Osiris Therapeutics, Inc, Baltimore, Maryland 21231 2001, USA
    Tissue Eng 4:415-28. 1998
  8. ncbi Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation
    S P Bruder
    Osiris Therapeutics, Inc, Baltimore, Maryland 21231 2001, USA
    J Bone Miner Res 13:655-63. 1998
  9. ncbi Distribution of cartilage molecules in the developing mouse joint
    J M Murphy
    Osiris Therapeutics Inc, Baltimore, MD 21231, USA
    Matrix Biol 18:487-97. 1999
  10. ncbi Stem cell therapy in a caprine model of osteoarthritis
    J Mary Murphy
    Osiris Therapeutics, Baltimore, Maryland 21231, USA
    Arthritis Rheum 48:3464-74. 2003

Collaborators

  • J Zaia
  • B Liu
  • M F Pittenger
  • A M Mackay
  • S P Bruder
  • Valerie Barron
  • Karen English
  • Eoin D O'Cearbhaill
  • Gemma E Rooney
  • Bernard P Mahon
  • J Mary Murphy
  • Anthony J Windebank
  • TIMOTHY O'BRIEN
  • Martin Maenz
  • Siobhan S McMahon
  • Marie A Punchard
  • Alexander Flügel
  • Linda Howard
  • Peter E McHugh
  • J M Murphy
  • Mary Murphy
  • Cathal Moran
  • Thomas Ritter
  • Peter Dockery
  • Ciara P Field-Corbett
  • David J Fink
  • Ernst B Hunziker
  • D Sterchi
  • A McIntosh
  • R Heinegård

Detail Information

Publications15

  1. ncbi Mesenchymal stem cells: clinical applications and biological characterization
    Frank P Barry
    Osiris Therapeutics Inc, 2001 Aliceanna Street, Baltimore, MD 21231, USA
    Int J Biochem Cell Biol 36:568-84. 2004
    ..These include the host immune response to implanted cells, the homing mechanisms that guide delivered cells to a site of injury and the differentiation in vivo of implanted cells under the influence of local signals...
  2. ncbi Mesenchymal stem cell therapy in joint disease
    Frank P Barry
    Osiris Therapeutics Inc, 2001 Aliceanns Street, Baltimore, MD 21231, USA
    Novartis Found Symp 249:86-96; discussion 96-102, 170-4, 239-41. 2003
    ..This treatment has the potential to stimulate regeneration of cartilage and retard the progressive destruction of the joint that typically occurs following injury...
  3. ncbi Biology and clinical applications of mesenchymal stem cells
    Frank P Barry
    Osiris Therapeutics Inc, 2001 Aliceanna St, Baltimore, MD 21231, USA
    Birth Defects Res C Embryo Today 69:250-6. 2003
    ..These are (1) the host immune response to implanted cells, (2) the homing mechanisms that guide delivered cells to a site of injury, and (3) differentiation of implanted cells under the influence of local signals...
  4. ncbi The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105)
    F P Barry
    Osiris Therapeutics Inc, 2001 Aliceanna Street, Baltimore, Maryland, 21231, USA
    Biochem Biophys Res Commun 265:134-9. 1999
    ..Endoglin on MSCs potentially plays a role in TGF-beta signalling in the control of chondrogenic differentiation of MSCs and also in mediating interactions between MSCs and haematopoietic cells in the bone marrow microenvironment...
  5. ncbi Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components
    F Barry
    Osiris Therapeutics, Inc, 2001 Aliceanna Street, Baltimore, Maryland 21231, USA
    Exp Cell Res 268:189-200. 2001
    ..These data allow us to define the phenotype of the differentiated cell and to understand in greater detail the sequential process of matrix assembly...
  6. ncbi The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells
    F Barry
    Osiris Therapeutics, Inc, Baltimore, Maryland 21231, USA
    Biochem Biophys Res Commun 289:519-24. 2001
    ..The role that CD73 may play in bone marrow stromal interactions and in the differentiation of MSCs is discussed...
  7. ncbi Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow
    A M Mackay
    Osiris Therapeutics, Inc, Baltimore, Maryland 21231 2001, USA
    Tissue Eng 4:415-28. 1998
    ..Increased understanding of the induction of chondrogenic differentiation should lead to further progress in defining the mechanisms responsible for the generation of cartilaginous tissues, their maintenance, and their regeneration...
  8. ncbi Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation
    S P Bruder
    Osiris Therapeutics, Inc, Baltimore, Maryland 21231 2001, USA
    J Bone Miner Res 13:655-63. 1998
    ..Together, these results provide evidence that ALCAM plays a critical role in the differentiation of mesenchymal tissues in multiple species across the phylogenetic tree...
  9. ncbi Distribution of cartilage molecules in the developing mouse joint
    J M Murphy
    Osiris Therapeutics Inc, Baltimore, MD 21231, USA
    Matrix Biol 18:487-97. 1999
    ..Fibromodulin may function in the early genesis of articular cartilage and COMP may be associated with elaboration of a weight-bearing chondrocyte matrix...
  10. ncbi Stem cell therapy in a caprine model of osteoarthritis
    J Mary Murphy
    Osiris Therapeutics, Baltimore, Maryland 21231, USA
    Arthritis Rheum 48:3464-74. 2003
    ....
  11. ncbi Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft
    Frank P Barry
    Regenerative Medicine Institute REMEDI, National Centre for Biomedical Engineering Science, National University of Ireland, Galway, Ireland
    Stem Cells Dev 14:252-65. 2005
    ..This comparison suggests new approaches to determine the contribution of different mechanisms to the successful use of MSC in regenerative medicine...
  12. ncbi IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells
    Karen English
    Mucosal Immunology Laboratory, Institute of Immunology, National University of Ireland Maynooth, Maynooth, Co Kildare, Ireland
    Immunol Lett 110:91-100. 2007
    ....
  13. ncbi Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation
    Karen English
    Mucosal Immunology Laboratory, Institute of Immunology, National University of Ireland Maynooth, Maynooth, Co Kildare, Ireland
    Immunol Lett 115:50-8. 2008
    ..These data demonstrate that MSC modulate the three cardinal features of DC maturation, providing the first demonstration of MSC interference with DC migration...
  14. doi Response of mesenchymal stem cells to the biomechanical environment of the endothelium on a flexible tubular silicone substrate
    Eoin D O'Cearbhaill
    National Centre for Biomedical Engineering Science, National University of Ireland, Galway, Galway, Ireland
    Biomaterials 29:1610-9. 2008
    ..However, gene expression results show the cells exhibit greater levels of SMC-associated markers alpha-smooth muscle actin and calponin (p<0.05)...
  15. doi Gene-modified mesenchymal stem cells express functionally active nerve growth factor on an engineered poly lactic glycolic acid (PLGA) substrate
    Gemma E Rooney
    Regenerative Medicine Institute, National University of Ireland, Galway, Ireland
    Tissue Eng Part A 14:681-90. 2008
    ..They are autologous, may be genetically modified to express neurotrophins, and are compatible with polymer surfaces that may be used as a potential delivery system...